What Are Chinese Pharma CEOs Ranting About? (Part 2 of 2)

16 Mar 2015

Top pharma executives get the chance to air their grievances during a once-a-year “meet the regulators” session in Beijing. In this second part of coverage of the meeting, China FDA director Wang Lifeng discusses marketing authorization holder pilots while CEOs including Betta’s Ding Lieming touch upon provincial tenders, orphan drugs and patent invalidity appeals.

BEIJING – During the March 4 “Meet the Regulators” session titled “Voice, Responsibility”, held on the sidelines of the annual gathering of congressional delegates in the Chinese capital, 40 pharmaceutical industry members meet dozens of regulators.

They included members of the National People’s Congress (NPC), which drafts legislation, and the China Political Consultative Conference (CPCC), which...